Nabriva Therapeutics PLC (NBRV) CEO Theodore Schroeder on Q4 2020 Results - Earnings Call TranscriptSeeking Alpha • 03/12/21
Nabriva Therapeutics Reports Fourth Quarter and Year End 2020 Financial Results and Provides Corporate UpdatesGlobeNewsWire • 03/11/21
Nabriva Therapeutics (NBRV) Is in Oversold Territory: What's Next?Zacks Investment Research • 03/09/21
Nabriva Therapeutics to Report 2020 Financial Results and Recent Corporate Highlights on March 11, 2021GlobeNewsWire • 03/03/21
Nabriva Therapeutics Announces $25.4 Million Registered Direct Offering Priced At-the-Market under Nasdaq RulesGlobeNewsWire • 03/01/21
Pomerantz LLP and Holzer & Holzer, LLC Announce a Notice of Pendency and Proposed Settlement of Class Action in LARRY ENRIQUEZ v. NABRIVA THERAPEUTICS PLC, et al.PRNewsWire • 02/26/21
Study Demonstrates Macrolide-Resistance in S. pneumoniae in the United States Exceeds 25 Percent Threshold Set in Current Community-Acquired Bacterial Pneumonia (CABP) Treatment GuidelinesGlobeNewsWire • 02/23/21
Nabriva Therapeutics to Participate in Upcoming Virtual Investor Conferences in JanuaryGlobeNewsWire • 01/05/21
Nabriva Therapeutics and Sinovant Sciences Restructure License Agreement for XENLETA for Community-Acquired Bacterial Pneumonia in ChinaGlobeNewsWire • 12/07/20
Nabriva Therapeutics plc's (NBRV) CEO Ted Schroeder on Q3 2020 Results - Earnings Call TranscriptSeeking Alpha • 11/09/20
Nabriva Therapeutics Reports Third Quarter 2020 Financial Results and Provides Corporate UpdatesGlobeNewsWire • 11/05/20
Nabriva Therapeutics to Report Third Quarter 2020 Financial Results on November 5, 2020GlobeNewsWire • 11/02/20
Nabriva’s XENLETA Demonstrates High Efficacy in Patients of Advanced Age with Community-Acquired Bacterial Pneumonia (CABP)GlobeNewsWire • 10/13/20
Nabriva Therapeutics Granted New Technology Add-On Payment for XENLETA® (lefamulin) and CONTEPO™ (fosfomycin) by Centers for Medicare & Medicaid ServicesGlobeNewsWire • 09/10/20
Nabriva Therapeutics Plc (NBRV) CEO Ted Schroeder on Q2 2020 Results - Earnings Call TranscriptSeeking Alpha • 08/09/20
Nabriva Therapeutics to Report Second Quarter 2020 Financial Results on August 6, 2020GlobeNewsWire • 08/03/20
Nabriva Therapeutics to Present at the 2020 Wedbush PacGrow Healthcare Virtual ConferenceGlobeNewsWire • 07/30/20
NABRIVA Receives European Approval for XENLETA® (lefamulin) for Treatment of Community-Acquired Pneumonia (CAP)GlobeNewsWire • 07/28/20